Max Krummel

Max Krummel's work experience spans multiple companies and roles. Max is currently the Founder and Partner of Foundery Innovations, Inc., where they lead a scientific R&D team focused on immunotherapeutic drug development. Prior to this, Max served as a Professor and Chair at the University of California, San Francisco, where they conducted research on immune system regulation. Max also founded Pionyr Immunotherapeutics, a company specializing in myeloid cell targeting. Max has served as an Advisory Board member for both Deciduous Therapeutics and Guardian Bio. Additionally, they are the Founder and Board Member of Solving for Science, a collaborative effort to improve the culture and application of scientific research.

Max Krummel attended the University of Illinois Urbana-Champaign from 1985 to 1989, where they obtained a Bachelor's degree in Chemistry and Biology. Max then pursued higher education at the University of California, Berkeley from 1989 to 1995, earning a Doctor of Philosophy (PhD) degree in Cell/Cellular and Molecular Biology. After completing their PhD, Krummel engaged in postdoctoral research at the Walter and Eliza Hall Institute from 1996 to 1998. Subsequently, they furthered their postdoctoral studies at Stanford University from 1998 to 2001. The specific degree name during their time at Stanford University is not provided.